share_log

Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Benzinga ·  May 29 09:00

Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ:CORT), offering a diverse set of opinions from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings40000
Last 30D10000
1M Ago20000
2M Ago10000
3M Ago00000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $40.5, a high estimate of $44.00, and a low estimate of $38.00. Observing a 1.25% increase, the current average has risen from the previous average price target of $40.00.

price target chart

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Corcept Therapeutics among financial experts becomes...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment